SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)
In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning effectiveness and tolerance. It was a prospective study which was accomplished in 100 ambulatory practice offices.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe AECB|
- Effectiveness and tolerance of/to the different therapies [ Time Frame: within the first 14 days ] [ Designated as safety issue: Yes ]
- Possible hospitalisation rate [ Time Frame: within the first 14 days ] [ Designated as safety issue: Yes ]
Biospecimen Retention: None Retained
|Study Start Date:||December 2009|
|Study Completion Date:||August 2010|
|Primary Completion Date:||August 2010 (Final data collection date for primary outcome measure)|
Drug: Moxifloxacin (Avelox, BAY12-8039)
Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
The study design was slightly changed to adapt the target population. Due to these changes the study was restarted on 8th December 2009.